Overall, these results indicate that the group of eight AML cell lines for which MEKi + PI3Ki cotreatment shows synergy presented higher phosphorylation on eEF2K activity markers (both eEF2 and eEF2K autocatalysis) as well as increased expression of PI3K pathway members and RAS. The gene discussed is PIK3CA; the disease is acute myeloid leukemia.